Sustained-release applications of montmorillonite interaction with amphetamine sulfate.
Urinary recovery studies showed that montmorillonite significantly affects the initial therapeutic levels of amphetamine sulfate. The combination of a 1:20 drug-montmorillonite complex with pure drug in a 1:1 ratio, based on amphetamine content, resulted in recovery profiles resembling those obtained from prolonged-release dosage forms. The 1:20 complex, pure drug, and combination formulations showed comparable bioavailability after 48 hr.
D000328:Adult; D000661:Amphetamine / Q000008:administration & dosage* / Q000652:urine; D001546:Bentonite / Q000494:pharmacology*; D001682:Biological Availability; D003692:Delayed-Action Preparations; D004347:Drug Interactions; D005260:Female; D006801:Humans; D008297:Male; D013997:Time Factors
D003692:Delayed-Action Preparations; D001546:Bentonite; D000661:Amphetamine